Protocol Ledger

NCT05909332 · Phase III · RECRUITING

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Interventional Phase III clinical trial protocol NCT05909332 sponsored by Fudan University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-20 Enrollment: 764 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05909332
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)764 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05909332
Protocol FieldVerified Registry Value
NCT IdentifierNCT05909332
Consolidated Lead SponsorFudan University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment764 participants (ESTIMATED)
Registered Start Date2023-06-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05909332
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Fujian Medical University Union HospitalFuzhou, ChinaOpen Hospital Dossier ->
Affiliated Hospital of Nantong UniversityNantong, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI